Status: Recruiting
Dual-Target CAR-NK Cells for Advanced Breast Cancer HER2+ TNBC
This study tests the safety and preliminary anti-tumor activity of an investigational dual-target chimeric antigen receptor natural killer (CAR-NK) cell therapy in adults with advanced breast cancer. After a tumor antigen assessment (HER2/ERBB2, MUC1, ROR1,TNBC cases mesothelin), each participant will receive the most suitable dual-target CAR-NK product for their tumor profile, following short-course lymphodepleting chemotherapy.
Participants needed: 60
Trial details
Phase: Phase 1, Phase 2Age: 18-75Biological sex: AllType: InterventionalSponsor: Beijing BiotechUpdated: Apr 6, 2026Locations: 1
Eligibility criteria
Histologically confirmed breast carcinoma that is locally advanced, unresectable... [+11]
Active, untreated central nervous system (CNS) metastases or leptomeningeal dise... [+7]